Literature DB >> 24130265

Health status has improved more in women than in men with rheumatoid arthritis from 1994 to 2009: results from the Oslo rheumatoid arthritis register.

C Austad1, T K Kvien1, I C Olsen1, T Uhlig2.   

Abstract

OBJECTIVE: To examine changes in patient reported outcome measures (PROs) over 15 years in a representative population of patients with rheumatoid arthritis (RA), with a particular focus on gender differences. PATIENTS AND METHODS: Patients in the Oslo RA register filled in questionnaires including the Modified Health Assessment Questionnaire (MHAQ), the Short-Form 36 (SF-36) with physical (PCS) and mental component summaries and derived utility (SF-6D), visual analogue scales (VAS) for pain, patient global assessment of disease (PtGA) and fatigue, and checklists of medication commonly used in the treatment of RA. Data were collected at five time points during a 15-year period from 1994. Mixed model analyses were used to analyse longitudinal changes in PROs from 1994 to 1996, 2001, 2004 and 2009.
RESULTS: Data were available from 829-1025 RA patients at each time point. PROs were statistically significantly improved from 1994 to 2009 (MHAQ, SF-36 PCS, SF-6D, pain VAS, PtGA VAS and fatigue VAS; all p<0.001), and also with clinically important improvement. Men reported significantly better health status than women in 1994, but women improved significantly more than men over 15 years with a reduction of the gender gap in 2009. Antirheumatic medication was increasingly used over 15 years with no gender differences.
CONCLUSIONS: RA patients reported statistically significantly improved health status for most PROs from 1994 to 2009. Women improved most, and although they still reported higher disease impact than men, the gender differences were small at the final data collection in 2009. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Epidemiology; Outcomes research; Rheumatoid Arthritis

Mesh:

Substances:

Year:  2013        PMID: 24130265     DOI: 10.1136/annrheumdis-2013-204014

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

1.  The burden of disease in rheumatoid arthritis.

Authors:  Till Uhlig; Rikke H Moe; Tore K Kvien
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

2.  Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal.

Authors:  Anand N Malaviya; S B Gogia
Journal:  Clin Rheumatol       Date:  2016-04-28       Impact factor: 2.980

3.  Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis.

Authors:  Ulf Bergström; Stefan Jovinge; Jerker Persson; Lennart T H Jacobsson; Carl Turesson
Journal:  Curr Ther Res Clin Exp       Date:  2018-07-23

4.  Are There Any Common Genetic Risk Markers for Rheumatoid Arthritis and Periodontal Diseases? A Case-Control Study.

Authors:  Susanne Schulz; Natalie Pütz; Elisa Jurianz; Hans-Günter Schaller; Stefan Reichert
Journal:  Mediators Inflamm       Date:  2019-02-12       Impact factor: 4.711

5.  rs2476601 in PTPN22 gene in rheumatoid arthritis and periodontitis-a possible interface?

Authors:  Susanne Schulz; Pauline Zimmer; Natalie Pütz; Elisa Jurianz; Hans-Günter Schaller; Stefan Reichert
Journal:  J Transl Med       Date:  2020-10-15       Impact factor: 5.531

6.  Socio-demographic determinants in the evolution of pain in inflammatory rheumatic diseases: results from ESPOIR and DESIR cohorts.

Authors:  Sushmithadev Kumaradev; Christian Roux; Jérémie Sellam; Serge Perrot; Thao Pham; Aline Dugravot; Anna Molto
Journal:  Rheumatology (Oxford)       Date:  2022-04-11       Impact factor: 7.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.